US biotech firm Celgene on Monday announced a deal to acquire the bio-pharmaceutical company Juno Therapeutics for $9 billion or $87 per share. The Seattle-based Juno is a leader in developing treatments for incurable blood cancers such as lymphoma, Celgene CEO Mark J. Alles said in a statement.
"Juno's advanced cellular immunotherapy portfolio and research capabilities strengthen Celgene's global leadership in hematology and adds new drivers for growth beyond 2020," Alles said. One Juno lymphoma treatment is expected to receive regulatory approval next year, with potential global sales of about $3 billion, the statement said. The merger pushes Celgene deeper into cancer treatments. This month, it acquired the blood disease biotech firm Impact Biomedicines for $7 billion.
Comments
Comments are closed for this article.